Biopharma hiring is broken in a way that’s easy to miss: we keep treating IP as a standalone function—when, in practice, it’s an operating system.
In other words, the “right” IP talent isn’t just about knowing patents. It’s about understanding how an I…

The Generic Cliff Doesn’t “Hit” — It’s Engineered Around.
If you’ve ever wondered why some pharma companies seem to “beat” expiring patents while others get crushed by the generic wave, the answer isn’t just luck or better legal strategy. It’s engine…

Patent thickets are the new moat—and biologics are the new battleground.
If you’ve ever wondered why some blockbuster drugs seem to face delays in competition for years (even when the “main” patent should be expiring), the answer is rarely a single p…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most companies don’t lose on patents because they “didn’t try.” They lose because they tried too late.
By the time a generic challenger, investor, or licensing partner is deep into …

Most teams treat formulation patents like a black box. That’s why they miss the design-around window.
In pharma, the “real” competitive advantage often isn’t the active ingredient—it’s the formulation. The release profile, stability, solubility, manufa…

Russia’s latest VED/SSM listing isn’t just another regulatory update—it’s a live-fire signal for how generics will (and won’t) enter the market.
Here’s the agitation: in pharma, timing is everything, but most teams still treat “patent expiry” like a ca…

Pharma pipelines don’t fail in the lab. They fail in the courtroom.
That’s the uncomfortable truth behind Freedom to Operate (FTO) work—and why the best teams treat it like a strategic discipline, not a one-time legal checkbox.
In a world where patents…

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copy” Into Differentiation—and Defense
In generic drug land, the default playbook is simple: file an ANDA, win on price, and let the market do the rest.
But that playbook is increasingly crowded—and …

Pharma IP teams are used to thinking in timelines: filing dates, priority windows, prosecution milestones, and—eventually—patent expiry. But in Russia, the clock can move in ways that don’t always show up in your standard global playbook.
A recent Drug…

Drug patent portfolios shouldn’t just sit on the shelf—they should be engineered to win.
In pharma, the default playbook is often “file early, hope for the best, and defend later.” But the market has changed. Litigation is no longer a rare event; it’…